Clinical Trial Update: Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study [Phase 2]

View source ↗

Summary

Extension study update for RA101495 in PNH patients who completed a prior Zilucoplan/RA101495 trial; the Phase 2 study is terminated with results posted in 2022…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• RA101495 (RA101495)

Snippet

Sponsor: Ra Pharmaceuticals, Inc. | Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 2 | Status: TERMINATED | Results posted: 2022-10-27